JP2012509344A5 - - Google Patents

Download PDF

Info

Publication number
JP2012509344A5
JP2012509344A5 JP2011537608A JP2011537608A JP2012509344A5 JP 2012509344 A5 JP2012509344 A5 JP 2012509344A5 JP 2011537608 A JP2011537608 A JP 2011537608A JP 2011537608 A JP2011537608 A JP 2011537608A JP 2012509344 A5 JP2012509344 A5 JP 2012509344A5
Authority
JP
Japan
Prior art keywords
formulation
amino acid
acid sequence
seq
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011537608A
Other languages
English (en)
Japanese (ja)
Other versions
JP5726085B2 (ja
JP2012509344A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/065084 external-priority patent/WO2010059787A1/en
Publication of JP2012509344A publication Critical patent/JP2012509344A/ja
Publication of JP2012509344A5 publication Critical patent/JP2012509344A5/ja
Application granted granted Critical
Publication of JP5726085B2 publication Critical patent/JP5726085B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011537608A 2008-11-20 2009-11-19 治療用タンパク質製剤 Active JP5726085B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11654108P 2008-11-20 2008-11-20
US61/116,541 2008-11-20
PCT/US2009/065084 WO2010059787A1 (en) 2008-11-20 2009-11-19 Therapeutic protein formulations

Publications (3)

Publication Number Publication Date
JP2012509344A JP2012509344A (ja) 2012-04-19
JP2012509344A5 true JP2012509344A5 (https=) 2015-04-02
JP5726085B2 JP5726085B2 (ja) 2015-05-27

Family

ID=41683048

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011537608A Active JP5726085B2 (ja) 2008-11-20 2009-11-19 治療用タンパク質製剤

Country Status (12)

Country Link
US (2) US20120027772A1 (https=)
EP (1) EP2358393A1 (https=)
JP (1) JP5726085B2 (https=)
KR (1) KR101676887B1 (https=)
CN (2) CN102281901A (https=)
AU (1) AU2009316592B2 (https=)
BR (1) BRPI0921947A2 (https=)
CA (1) CA2737045C (https=)
HK (1) HK1244426A1 (https=)
IL (1) IL211670A (https=)
MX (1) MX2011004748A (https=)
WO (1) WO2010059787A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0717638A2 (pt) 2006-10-27 2013-11-12 Genentech Inc Anticorpors e imunoconjugados e usos para os mesmos
BR112012031727B1 (pt) * 2010-06-15 2022-03-29 Genmab A/S Conjugado de droga-anticorpo, composição farmacêutica, e, uso do conjugado de droga- anticorpo
EP2399604A1 (en) * 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
CN107233569B (zh) 2011-10-25 2021-08-31 普罗西纳生物科学有限公司 抗体制剂和方法
WO2015183989A1 (en) * 2014-05-27 2015-12-03 Navigen, Inc. Arf6 inhibitors and methods of synthesis and use thereof
JP2018533930A (ja) * 2015-10-02 2018-11-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性t細胞活性化抗原結合分子
MX2019011769A (es) 2017-04-03 2019-11-07 Hoffmann La Roche Anticuerpos que se unen a steap-1.
US20200289621A1 (en) * 2017-09-22 2020-09-17 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent stability
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體-藥物共軛物的組合治療癌症之方法
JP7840636B2 (ja) * 2018-04-02 2026-04-06 アムジェン インコーポレイテッド エレヌマブ組成物及びその使用
TW202506732A (zh) 2018-05-07 2025-02-16 丹麥商珍美寶股份有限公司 使用抗pd-1抗體與抗組織因子抗體-藥物共軛體之組合以治療癌症之方法
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子(vegf)抗體與抗組織因子(tf)抗體-藥物共軛體之組合以治療癌症之方法
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
EP4326766A1 (en) * 2021-04-23 2024-02-28 Amgen Inc. Anti-tslp antibody compositions and uses thereof
CN118812648A (zh) * 2024-07-28 2024-10-22 青岛大学附属医院 一种基于steap-1的t细胞抗原表位肽及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003520828A (ja) * 2000-01-27 2003-07-08 ジェネティクス インスティテュート,エルエルシー Ctla4(cd152)に対する抗体、これを含む結合体、およびその使用
JP5485489B2 (ja) * 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
JP5052736B2 (ja) * 2001-05-30 2012-10-17 中外製薬株式会社 タンパク質製剤
MXPA04000747A (es) * 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
JP2003128575A (ja) * 2001-10-25 2003-05-08 Mochida Pharmaceut Co Ltd 脳腫瘍治療剤
CN101721362B (zh) * 2002-02-14 2018-07-03 中外制药株式会社 包含抗体的溶液制剂
EP1558645B1 (en) * 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
AU2004319915B9 (en) * 2004-04-22 2011-12-22 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
DK1791565T3 (en) * 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
BRPI0717638A2 (pt) * 2006-10-27 2013-11-12 Genentech Inc Anticorpors e imunoconjugados e usos para os mesmos

Similar Documents

Publication Publication Date Title
JP2012509344A5 (https=)
JP7472210B2 (ja) 有効性の改善および毒性の減少のための、抗体およびsn-38からなるイムノコンジュゲートの投薬
JP7245239B2 (ja) Ror1抗体免疫複合体
JP2015528818A5 (https=)
ES2819573T3 (es) Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A
JP2015527318A5 (https=)
JP2015531750A5 (https=)
ES2988698T3 (es) Conjugados de fracciones de unión a la camptotecina
ES2945533T3 (es) Inmunoconjugados con un enlace escindible intracelularmente
ES2892525T3 (es) Uso neoadyuvante de conjugados anticuerpo-fármaco
AU2014293670B2 (en) Antibody-SN-38 immunoconjugates with a CL2A linker
JP2019146572A5 (https=)
JP2017503011A5 (https=)
JP2017522861A5 (https=)
JP2015523380A5 (https=)
JP2015527319A5 (https=)
CN105209068A (zh) 用于靶向癌症治疗的缀合至抗体的高效2-吡咯啉多柔比星的前药形式(p2pdox)
JP2011500725A5 (https=)
JP2021521143A5 (https=)
EP3316885A1 (en) Antibody-sn-38 immunoconjugates with a cl2a linker
JP2022513684A5 (https=)
JP2024530368A5 (https=)
JP2011505371A5 (https=)
EP4642488A1 (en) Antibody drug conjugates
JP2015529656A5 (https=)